POINT Biopharma, a biopharmaceutical company, went public via a SPAC merger with Research Alliance, a special purpose acquisition company, in a $165m deal. “We are excited to be entering the public markets at a time when innovative radiopharmaceuticals have gained so much momentum and are being recognized as potential options for many types of cancer, including large indications such as prostate cancer. We want to thank our entire team, our new and existing shareholders, and all those involved in making this transaction a success. We look forward to bringing the next-generation of precision oncology medicines to patients," Joe McCann, POINT CEO.